Clinical Trials Browser

lenvatinib × Thoracic × Clear all

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04938817 2026-02-09

KEYNOTE-B98

Phase 1/2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT05078931 2025-07-30

A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Phase 2 Active not recruiting

NSCLC

NCT04924101 2025-07-23

KEYNOTE-B99

Phase 2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT06318286 2025-05-25

PENINSULA

Phase 2 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04676412 2025-04-04

LEAP-007

Phase 3 Completed

107 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06068153 2024-11-20

AMBER

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT04287829 2024-11-05

PEMMELA

Phase 2 Active not recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04951947 2024-09-19

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT05258279 2024-08-28

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

Phase 2 Active not recruiting

Non-squamous Non-small-cell Lung Cancer

NCT05296603 2024-01-10

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer

Phase 2 Unknown

Small Cell Lung Carcinoma

NCT05832827 2023-10-23

Artemis

Phase 2 Recruiting

Thymoma

NCT06028633 2023-09-13

Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Patients

Phase 2 Not yet recruiting

Advanced Non-squamous Non-small-cell Lung Cancer

NCT05001724 2023-04-25

KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent

Phase 2/3 Terminated

Advanced Non-small Cell Lung Cancer

NCT04875585 2022-08-24

INNWOP1

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04989322 2021-12-08

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

Phase 2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03006887 2021-05-20

Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1 Completed

6 enrolled 27 charts

GenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Endometrial Neoplasms

NCT01529112 2017-09-26

A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Phase 2 Completed

135 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung